Related Experiment Videos
Background of the antisense oligonucleotide approach to chemotherapy
1Hybridon, Inc., Cambridge, MA 02139, USA.
Antisense & Nucleic Acid Drug Development
|June 1, 1997
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
A new contrast in MR mammography by means of chemical exchange saturation transfer (CEST) imaging at 3 Tesla: preliminary results.
RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin·2011
[Diffusion-weighted MRI of the prostate].
Der Radiologe·2011
Comparison of diagnostic quality and accuracy in color-coded versus gray-scale DCE-MR imaging display.
International journal of computer assisted radiology and surgery·2009
Diagnosis of pulmonary metastases with helical CT: the effect of imaging techniques.
The Thoracic and cardiovascular surgeon·2008
Progress in the delivery of therapeutic oligonucleotides: organ/cellular distribution and targeted delivery of oligonucleotides in vivo.
Antisense & nucleic acid drug development·2003
Safety of CpG oligodeoxynucleotides in veterinary species.
Antisense & nucleic acid drug development·2003
Coupling of RNAi-mediated target downregulation with gene replacement.
Antisense & nucleic acid drug development·2003
Inhibitory oligonucleotides block the induction of AP-1 transcription factor by stimulatory CpG oligonucleotides in B cells.
Antisense & nucleic acid drug development·2003
Evaluation of C-5 propynyl pyrimidine-containing oligonucleotides in vitro and in vivo.
Antisense & nucleic acid drug development·2003
Effects of base modifications on antisense properties of 2'-O-methoxyethyl and PNA oligonucleotides.
Antisense & nucleic acid drug development·2003
A marine-derived meroterpenoid inhibits colorectal cancer via PI3K pathway modulation in mice.
Marine life science & technology·2026
SGLT2 inhibitor therapy is associated with IL-10/TGF-α/sVEGFR3 signalling and adipose tissue remodelling in advanced heart failure.
Journal of molecular and cellular cardiology plus·2026